Anika Therapeutics Inc
Затворен
СекторЗдравеопазване
13.35 -2.41
Преглед
Промяна на цената на акция
24 ч
Минимум
13.16
Максимум
13.66
Приходи | -3.6M -311K |
|---|---|
Продажби | -2M 31M |
EPS | -0.01 |
Марж на печалбата | -1.017 |
Служители | 235 |
EBITDA | -5.6M -712K |
Препоръки | Купи |
|---|---|
12-месечна прогноза | +66.55% upside |
Пазарна капитализация | -65M 195M |
|---|---|
Предишно отваряне | 15.76 |
Предишно затваряне | 13.35 |
Anika Therapeutics Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Anika Therapeutics Inc Прогноза
Ценова цел
By TipRanks
66.55% нагоре
12-месечна прогноза
Среден 23 USD 66.55%
Висок 23 USD
Нисък 23 USD
Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anika Therapeutics Inc през последните три месеца.
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
